Όλο το DSpace

Εμφάνιση απλής εγγραφής

Outcome of refractory to conventional and/or biologic treatment adult Still's disease following canakinumab treatment: Countrywide data in 50 patients

dc.creatorLaskari K., Tektonidou P.M.G., Katsiari P.C., Athanassiou P., Dimopoulou D., Gerodimos C., Salamaliki C., Papagoras P.C., Settas P.L., Vassilopoulos P.D., Voulgari P.P.V., Zakalka M., Georgiadis A., Gkoni G., Daoussis P.D., Dimitroulas P.T., Iliou C., Kallitsakis I., Grika E.P., Mavragani P.C., Pikazis P.D., Raftakis J., Sarikoudis T., Kougkas N., Soukera D., Theodorou E., Tsatsani P., Tsiakou E., Vlachoyiannopoulos P.P., Vosvotekas G., Sfikakis P.P.P.en
dc.date.accessioned2023-01-31T08:48:58Z
dc.date.available2023-01-31T08:48:58Z
dc.date.issued2021
dc.identifier10.1016/j.semarthrit.2020.10.011
dc.identifier.issn00490172
dc.identifier.urihttp://hdl.handle.net/11615/75698
dc.description.abstractObjective: To assess the efficacy and safety of the IL-1b inhibitor canakinumab in all adults with refractory Still's disease identified from the National Organization For Medicines for off-label drug use. Methodsen
dc.language.isoenen
dc.sourceSeminars in Arthritis and Rheumatismen
dc.source.urihttps://www.scopus.com/inward/record.uri?eid=2-s2.0-85098193236&doi=10.1016%2fj.semarthrit.2020.10.011&partnerID=40&md5=298475a7497abe2343fbb7c76350140c
dc.subjectabatacepten
dc.subjectanakinraen
dc.subjectcanakinumaben
dc.subjectcorticosteroiden
dc.subjectimmunoglobulinen
dc.subjectmethotrexateen
dc.subjectmethylprednisoloneen
dc.subjecttocilizumaben
dc.subjecttumor necrosis factor inhibitoren
dc.subjectantirheumatic agenten
dc.subjectbiological producten
dc.subjectcanakinumaben
dc.subjectmonoclonal antibodyen
dc.subjectadolescenten
dc.subjectadulten
dc.subjectadult onset Still diseaseen
dc.subjectageden
dc.subjectArticleen
dc.subjectclinical articleen
dc.subjectcohort analysisen
dc.subjectdisease activityen
dc.subjectdisease resistanceen
dc.subjectdrug dose intensificationen
dc.subjectdrug efficacyen
dc.subjectdrug megadoseen
dc.subjectdrug safetyen
dc.subjectdrug withdrawalen
dc.subjectfemaleen
dc.subjectfollow upen
dc.subjectgenital tract infectionen
dc.subjecthumanen
dc.subjectleukopeniaen
dc.subjectlongitudinal studyen
dc.subjectmacrophage activation syndromeen
dc.subjectmaleen
dc.subjectmonotherapyen
dc.subjectmouth infectionen
dc.subjectmulticenter studyen
dc.subjectonset ageen
dc.subjectpneumoniaen
dc.subjectpriority journalen
dc.subjectrelapseen
dc.subjectremissionen
dc.subjectrespiratory tract infectionen
dc.subjectretrospective studyen
dc.subjectskin infectionen
dc.subjectsoft tissue infectionen
dc.subjecttreatment outcomeen
dc.subjecttreatment responseen
dc.subjecturinary tract infectionen
dc.subjectclinical trialen
dc.subjectoff label drug useen
dc.subjecttreatment outcomeen
dc.subjectAdulten
dc.subjectAntibodies, Monoclonal, Humanizeden
dc.subjectAntirheumatic Agentsen
dc.subjectBiological Productsen
dc.subjectHumansen
dc.subjectOff-Label Useen
dc.subjectRetrospective Studiesen
dc.subjectStill's Disease, Adult-Onseten
dc.subjectTreatment Outcomeen
dc.subjectW.B. Saundersen
dc.titleOutcome of refractory to conventional and/or biologic treatment adult Still's disease following canakinumab treatment: Countrywide data in 50 patientsen
dc.typejournalArticleen


Αρχεία σε αυτό το τεκμήριο

ΑρχείαΜέγεθοςΤύποςΠροβολή

Δεν υπάρχουν αρχεία που να σχετίζονται με αυτό το τεκμήριο.

Αυτό το τεκμήριο εμφανίζεται στις ακόλουθες συλλογές

Εμφάνιση απλής εγγραφής